ClinicalTrials.gg
CompletedNCT04672772Updated Mar 23, 2022

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

An observational study in Squamous Cell Carcinoma of the Head and Neck, sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Completed at 20 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
531
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain — 36 open to participants now, 70 under way, 14 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Spain.

Started
2020
with 15 others
Observational
6 of 167
2 open now
Registered
88th of 167
by date
Lead sponsor
4 of 167
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Among the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, this one is one of 16 that started in 2020, is one of 6 observational ones, and was the 88th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

36 of the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, or all of them as a file.
02

Study summary

Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Assignment of a patient to a specific therapeutic strategy has been already decided in the past according to normal routine clinical practice; the decision to prescribe a specific treatment (between January 2012 and December 2018) was clearly dissociated from the decision to include a patient in the present study.

The investigators will retrospectively collect the information for 500 patients diagnosed with recurrent and/or metastatic SCCHN treated with a cetuximab plus paclitaxel regimen as first line for unresectable recurrent and/or metastatic disease, starting treatment with the defined cetuximab plus paclitaxel regimen, in 20 hospital members of the "Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)", who express consent to participate in the study or have not explicitly withheld consent for use of their data. The information from the patients' medical records will be collected through the online database of the TTCC Group.

Read the detailed description

Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) with the restriction that the data collection will only be clinical data from patients who received paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab that could have been switched to biweekly during the maintenance phase.

The main objective will be to estimate the Progression-free survival (PFS) in patients treated with paclitaxel 80 mg/m2 as a starting dose, with weekly cetuximab that could have been switched to biweekly during the maintenance phase, as first line for recurrent and/or metastatic SCCHN.

Secondary objectives include:

To determine the Overall Response Rate (ORR), Best Overall Response (BOR), Disease Control Rate (DCR), overall survival (OS), duration of response (DoR), and safety in patients treated with the defined cetuximab plus paclitaxel regimen.

To evaluate the percentage of long disease-free survivors (defined as patients disease-free and alive at 2 years), and evaluate the percentage of long non-disease-free survivors (defined as patients not disease free, but alive at 2 years.

Analyses of patient outcomes by prognostic subgroups.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • Cetuximab
  • Paclitaxel
  • recurrent and/or metastatic
  • retrospective observational study
  • Squamous Cell Carcinoma of Head and Neck
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients diagnosed with recurrent and/or metastatic SCCHN treated with a cetuximab plus paclitaxel regimen as first line for unresectable R/M disease, starting treatment with the defined cetuximab plus paclitaxel regimen, between January 2012 and December 2018 in 20 hospital members of the "Grupo Español de Tratamiento de Tumores de Cabeza y Cuello", who express consent to participate in the study or have not explicitly withheld consent for use of their data.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed recurrent and/or head and neck squamous-cell carcinoma including oral cavity, oropharynx, hypopharynx and larynx.

Note: Histological confirmation is required at the diagnosis of the primary. Not for recurrence and/or metastatic stages when radiological or clinical confirmation is valid

  • Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a regimen in recurrent and/or metastatic disease.
  • Start of first cycle of paclitaxel plus cetuximab between 1 January 2012, and 31 December 2018.
  • Aged ≥ 18 years at the time of diagnosis of R/M SCCHN.
  • Voluntary written consent, if applicable*

    • Note: Waiver of consent could be acceptable after all reasonable efforts and procedures have been followed and exhausted, and when an explicit refusal to sign the or refusal for use of data, or a revocation of consent by the patient has not been obtained.

Exclusion criteria

Exclusion Criteria:

  • Patients with confirmed R/M SCCHN, who have also an unknown primary tumor or nasopharyngeal cancer or a non-squamous head \& neck cancer.
  • Patients who received the paclitaxel and cetuximab regimen for the first time in recurrent and/or disease as a second or subsequent line.
  • Eastern Cooperative. Oncology Group () performance status > 2.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
531 participants (actual)
Patient registry
No

Groups and cohorts

  • Recurrent and/or metastatic SCCHN

    Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.

    Drug: Cetuximab · Drug: Paclitaxel

Interventions

  • Weekly cetuximab at starting dose, that could be switched to biweekly

  • Paclitaxel at starting dose of 80 mg/m2

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    The PFS time is defined as the time from start of study treatment (first administration of cetuximab or paclitaxel) to the date of progression or death, whichever occurs first. In patients without a PFS event, the PFS time will be censored on the date of the last radiological evaluation or on the date of the last study treatment received if the tumor response has not been evaluated after start of study treatment. If no PFS was observed prior to start of second line treatment, then the PFS time will be censored at the first date of second line treatment.

    Time frame: Through study completion, average 1 year

Secondary outcomes

  1. Best Overall Response (BOR)

    Best overall response during study treatment with the categories complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) or not available (NA), as assessed by the responsible physician. The method used to assess BOR (e.g. RECIST and version) will be also recorded.

    Time frame: Through study completion, average 1 year

  2. Overall Response Rate (ORR)

    Overall response rate, defined as the proportion of patients with CR or PR as BOR.

    Time frame: Through study completion, average 1 year

  3. Disease Control Rate (DCR)

    The proportion of patients with CR, PR or SD as BOR.

    Time frame: Through study completion, average 1 year

  4. Frequency of Adverse Events (AEs)

    Safety will be studied as function of AEs frequency: The number of adverse events classified by type and intensity

    Time frame: Through study completion, average 1 year

  5. Overall survival (OS)

    Defined as time from start of study treatment until date of death due to any cause. In patients without death the OS time is censored at the last date known to be alive.

    Time frame: Through study completion, average 1 year

  6. Relative dose intensity (RDI)

    Relative dose intensity (RDI) defined as amount of drug administered per unit of time expressed as the fraction of that defined in the standard regimen

    Time frame: Through study completion, average 1 year

  7. Dose-related and compliance data

    Frequency and magnitude of dose interruptions, dose modifications and discontinuation of treatment classified by the cause of discontinuation including adverse events, relapse, medical decision, patient decision, death and loss of follow-up.

    Time frame: Through study completion, average 1 year

  8. Duration of Response (DOR)

    Defined as the time from the first occurrence of PR or CR as BOR until PD or death, whichever occurs first in patients with CR or PR as BOR. The censoring rules specified for PFS will be also applied for duration of response.

    Time frame: Through study completion, average 1 year

  9. Proportion of long disease-free survivors

    The proportion of patients alive and disease-free at 2 years after start of study treatment. Only disease-free patients under first line treatment should be counted.

    Time frame: Through study completion, average 1 year

07

Study locations

20 sites
  • Hospital Universitario Virgen de las Nieves
    Granada, Andalucia 18014, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, Andalucia 29010, Spain
  • Hospital Universitario Virgen de Valme
    Sevilla, Andalucia 41014, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, Aragon 50009, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Virgen de la Salud
    Toledo, Castilla La Mancha 45004, Spain
  • Hospital Universitario de Salamanca
    Salamanca, Castilla Y Leon 37007, Spain
  • Institut Catalá d'Oncologia (ICO) Badalona
    Badalona, Cataluña 08916, Spain
  • Institut Catalá d'Oncologia (ICO) Girona
    Girona, Cataluña 17007, Spain
  • Hospital Duran i Reynalds (ICO-Hospitalet)
    Hospitalet de Llobregat, Cataluña 08908, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, Comunitat Valenciana 46026, Spain
  • Centro Oncológico de Galicia
    A Coruña, Galicia 15009, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, Galicia 27003, Spain
  • Hospital Universitario Son Espases
    Palma De Mallorca, Islas Baleares 07120, Spain
  • Complejo Hospitalario Navarra (PAMPLONA)
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Canarias (TENERIFE)
    San Cristobal de la Laguna, Tenerife 38320, Spain
  • Hospital de Mar
    Barcelona, 08003, Spain
  • Hospital Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Universitario Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jan 2022, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2020
First posted
Dec 17, 2020
StartActual
Dec 18, 2020
Primary completionActual
Jan 17, 2022
CompletionActual
Jan 17, 2022
Last update
Mar 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04672772
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Dec 18, 2020
Primary completion
Jan 17, 2022
Completion
Jan 17, 2022
Last update
Mar 23, 2022

Study contacts

Beatriz Cirauqui Cirauqui, M.D. Ph.D.
principal investigator · Institut Catalá d'Oncologia (ICO) Badalona
Jordi Rubió Casadevall, M.D. Ph.D.
principal investigator · Institut Catalá d'Oncologia (ICO) Girona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion